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In this report we explore the use of MALDI-FTICR mass
spectrometry for the quantitative analysis of five HIV-1
protease inhibitors in cell lysates. 2,5-Dihydroxybenzoic
acid (DHB) was used as the matrix. From a quantitative
perspective, DHB is usually a poor matrix due to its poor
shot-to-shot and poor spot-to-spot reproducibilities. We
found that the quantitative precisions improved signifi-
cantly when DMSO (dimethylsulfoxide) was added to the
matrix solution. For lopinavir and ritonavir, currently
the most frequently prescribed HIV-1 protease inhibitors,
the signal-to-noise ratios improved significantly when
potassium iodide was added to the matrix solution. The
mean quantitative precisions, expressed as % relative
standard deviation, were 6.4% for saquinavir, 7.3% for
lopinavir, 8.5% for ritonavir, 11.1% for indinavir, and
7.2% for nelfinavir. The mean quantitative accuracies,
expressed as % deviation, were 4.5% for saquinavir, 6.0%
for lopinavir, 5.9% for ritonavir, 6.6% for indinavir, and
8.0% for nelfinavir. The concentrations measured for the
individual quality control samples were all within 85–117%
of the theoretical concentrations. The lower limits of
quantification in cell lysates were 4 fmol/µL for saquinavir,
16 fmol/µL for lopinavir, 31 fmol/µL for ritonavir, and
100 fmol/µL for indinavir and nelfinavir. The mean mass
accuracies for the protease inhibitors were E0.28 ppm
using external calibration. Our results show that MALDI-
FTICR mass spectrometry can be successfully used for
precise, accurate, and selective quantitative analyses of
HIV-1 protease inhibitors in cell lysates. In addition, the
lower limits of quantification obtained allow clinical ap-
plications of the technique.
Quantitative drug analysis using matrix-assisted laser desorp-
tion/ionization (MALDI) mass spectrometry is normally hampered
by poor reproducibility of the signal intensities and by the
presence of matrix-derived signals (leading to the so-called
chemical noise) in the low mass range, i.e., below 1000 Da. As a
consequence, electrospray ionization (ESI), in particular in com-
bination with a triple quadrupole mass analyzer, is normally
preferred. When operated in the selected reaction monitoring
mode (SRM), the triple quadrupole mass analyzer selectively
measures unique fragments of the analyte(s) and internal stan-
dard(s). The ESI ion source can be coupled to a high pressure
liquid chromatograph (HPLC), which further increases the assay’s
selectivity with concomitant decrease of ion suppression effects.
However, MALDI offers certain advantages over ESI for the
quantitative analysis of drugs as well as for the analysis of other
compounds: it is capable of a higher sample throughput,1 samples
can be conveniently stored on the target plate for future reanaly-
sis,2 and MALDI is less susceptible to ion suppression.3
Various approaches have been developed to improve the
performance of MALDI for the quantitative analysis of drugs,
which aim to eliminate the disadvantages normally associated with
MALDI, viz., the poor reproducibility of signal intensities and the
presence of matrix-derived chemical noise.4 Thus, high molecular
weight matrixes,5–9 additives,10 and matrixless target plates11,12
have been used to decrease and even to eliminate the matrix-
derived chemical noise in the low mass range. The reproducibility
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can be significantly increased by using ionic liquid matrixes,13
internal standards, sophisticated sample/matrix spotting devices14
and prestructured target plates,15 or by averaging out many
spectra of a single sample. These approaches have led to the
successful development of various quantitative drug assays using
MALDI-TOF,8,9,16,17 MALDI-q-TOF,18,19 and MALDI-triple qua-
drupole1,18,20,21 mass spectrometry.
Currently, no assays have been described which use MALDI-
FTICR for the quantitative analysis of drugs. The advantage of
MALDI-FTICR over other types of MALDI mass spectrometers
results from its high resolving power and mass accuracy, which
significantly increase the selectivity of the assay; in particular this
will be the case when the molecular ions of the analyte and internal
standard are used for quantitative analysis, i.e., from a full mass
spectrum (MS mode).
In this study, we assess the quantitative performance of
MALDI-FTICR mass spectrometry for the analysis of HIV-1
protease inhibitors in lysates of peripheral blood mononuclear cells
(PBMCs).
EXPERIMENTAL SECTION
Chemicals. Lopinavir (LPV; C37H48N4O5; monoisotopic mo-
lecular mass 628.362 47 Da) and ritonavir (RTV; C37H48N6O5S2;
monoisotopic molecular mass 720.312 76 Da) were kindly donated
by Abbott Laboratories (Illinois). Saquinavir (SQV; C38H50N6O5;
monoisotopic molecular mass 670.384 27 Da) was kindly donated
by F. Hoffmann-La Roche (Basel, Switzerland). Nelfinavir (NFV;
C32H45N3O4S; monoisotopic molecular mass 567.313 08 Da) was
kindly donated by Pfizer (Groton, CT), and indinavir (IDV;
C36H47N5O4; monoisotopic molecular mass 613.362 81 Da) was
kindly donated by Merck (Rahway, NJ). Potassium iodide was
obtained from Sigma-Aldrich. 2,5-Dihydroxybenzoic acid (DHB)
was obtained from Bruker Daltonics (Germany).
Peripheral Blood Mononuclear Cells. Peripheral blood
mononuclear cells (PBMCs) were obtained from a buffy coat
(Sanquin, Rotterdam, The Netherlands) using a standard Ficoll
density gradient. The PBMCs were extracted overnight in
methanol at 5 °C. The next day, the PBMC lysates were collected,
water was added to the samples until the water-to-methanol ratio
was 3:1, and the PBMC lysates were loaded onto a 96-well solid
phase extraction plate (Oasis HLB µelution plate, Waters).
Subsequently, the samples were washed twice with 200 µL of
methanol/water (1:3 v/v). Next, the samples were eluted from
the column with 100 µL of methanol. The samples were dried in
a SpeedVac (Savant) and stored at-80 °C until the day of analysis.
Mass Spectrometry. To study the effect of various DHB
preparations on the signal intensities and % CV of the analyte-to-
internal standard ratios, a mixture of five pure HIV protease
inhibitors was analyzed with four different DHB preparations:
DHB ) 10 mg/mL DHB in MeCN/water (1/1); DHB + DMSO
) 10 mg/mL DHB in MeCN/water/DMSO (9/9/2); DHB + KI
) 10 mg/mL DHB + 10 mM KI in MeCN/water (1/1); DHB +
KI + DMSO ) 10 mg/mL DHB + 10 mM KI in MeCN/water/
DMSO (9/9/2). For each DHB preparation, four technical
replicates, i.e., four spots on the target plate, were measured
(1 µL per spot).
For quantitative analysis of HIV protease inhibitors in cell
lysates, the samples were prepared by reconstituting the dried
PBMC lysates in 10 µL of water/MeCN/DMSO (9/9/2 v/v/v)
containing 10 mg/mL DHB, 10 mM KI, analyte at various
concentrations, and 1 pmol/µL internal standard. Technical
replicates of each calibrator were spotted on different positions
on a 400 µm AnchorChip target plate (Bruker Daltonics, Germany)
(1 µL per spot). Drying of the samples was assisted with a heat
blower.
Samples were measured on an APEX IV Qe 9.4 T FTICR mass
spectrometer (Bruker Daltonics) equipped with the first version
of the vacuum Combisource and a 20 Hz nitrogen laser with
irradiation area of ∼200 µm.22 Xmass version 7.0.8 was used to
operate the mass spectrometer, and DataAnalysis version 3.4 was
used for data analysis (both from Bruker Daltonics). A multishot
accumulation was used as recommended by O’Connor et al., Mize
et al., and Moyer et al.23–25 Ions produced by 10 laser shots were
accumulated in the storage hexapole, transferred to the FTICR
cell, and scanned for 0.78 s (TD size 512 Kb). Fifty scans were
summed for each mass spectrum. The acquisition mass range was
m/z 500-1000. The mass spectra were subsequently apodized and
zerofilled twice. An external mass calibration was applied using a
quadratic equation.
Quantitative Analysis of HIV Protease Inhibitors in Cell
Lysates. Two data sets (A and B) were used to assess the
quantitative performance of the MALDI-FTICR assay. Data set A
was used to construct the calibration curve while data set B was
used as quality controls and vice versa. For each sample in a data
set, three spots on the target plate, i.e., three technical replicates,
were measured. The quantitative precisions were obtained by
calculating the % relative standard deviation of the analyte-to-
internal standard ratio of the three replicate analyses of each
sample. The mean analyte-to-internal standard ratios of the three
replicate analyses were used to construct the calibration curve
(calibrators) or to check the quantitative accuracies (quality
controls). The mean analyte-to-internal standard ratios and analyte
concentrations were log 10-transformed, and a linear unweighed
curve was fitted through the data points.
RESULTS AND DISCUSSION
Choice of Matrix. Small molecule analysis by MALDI mass
spectrometry is normally hampered by the presence of matrix-
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derived chemical noise in the low mass range, i.e., below 1000
Da,26 the bane of any MALDI practitioner. The use of a high
molecular weight matrix is one way to overcome this phenom-
enon.7 We have recently developed a quantitative assay for HIV
protease inhibitors on a MALDI-TOF mass spectrometer using
the high molecular weight matrix meso-tetrakis(pentafluorophe-
nyl)porphyrin (F20TPP).8,9 The molecular weight of F20TPP is
974.6 Da, and so the only matrix-derived peaks which can be
observed in the low mass range result from dissociation of the
matrix or from matrix impurities. Thus, using a TOF analyzer,
we observed, as expected, only a few peaks in the low mass range,
making F20TPP eminently suitable as a matrix in TOF analyses.
We also attempted to use the F20TPP matrix on our MALDI-
FTICR mass spectrometer. In contrast to our previous MALDI-
TOF experiments, extensive fragmentation of the F20TPP matrix
was observed in our FTICR experiments which resulted in matrix-
derived interfering signals in the low mass range. Long-lived
metastable decay of ions formed in the MALDI source has been
extensively reported in the literature.27–34 The metastable frag-
mentations in FTICR are the result of the relatively long ion
lifetime (1 s) of the ions prior to detection in FTICR, compared
to the much shorter lifetimes associated with more conventional
MS techniques, such as TOF (10-4 s), and thus they are a direct
consequence of RRKM theory.35 For example, ions with a rate
constant (k) of 103 s-1 fragment on average in 10-3 seconds.36
These ions formed in the MALDI process could thus easily survive
the TOF time frame but would generate extensive fragmentation
in FTICR.28 In the same vein, noncovalent matrix adduct ions are
expected to be metastable on the FTICR time frame, and
dissociation is thus expected. This indeed appears to be the case;
using our FTICR instrument, the matrix DHB hardly shows any
chemical noise. Therefore, DHB was tested as a matrix for the
FTICR analysis of the HIV-1 protease inhibitors.
Matrix Preparation. We evaluated four different matrix
solutions: DHB only, DHB with DMSO, DHB with KI, and DHB
with both DMSO and KI, see Table 1. As can be seen from this
table, the highest S/N ratios were obtained for the protonated
forms of nelfinavir, indinavir, and saquinavir, i.e., when DHB was
used without the addition of KI. In contrast, the highest S/N ratios
for lopinavir and ritonavir were observed when DHB was used
with the addition of KI. DHB crystallizes in an inhomogeneous
way when it is spotted according to the widely used dried droplet
protocol (at ambient temperature). Because of this inhomoge-
neous crystallization, one needs to search for so-called sweet spots
in the sample/matrix crystals. In general, better quantitative
precisions are obtained when the sample/matrix crystals have a
homogeneous appearance. Therefore, we added DMSO to the
matrix solution. With the use of DMSO, the samples dry at a much
slower rate and dense homogeneous DHB crystals are formed,
even when dried using a heat blower. As shown in Table 2, the
quantitative precisions improved significantly when DMSO was
added to the DHB solution. In addition, as shown in Table 1, the
S/N of the potassiated HIV-1 protease inhibitors also improved
by adding DMSO to the matrix solution.
Quantitative Analysis of HIV Protease Inhibitors in Cell
Lysates. Our goal was to develop one assay for the quantitative
analysis of five HIV-1 protease inhibitors. As shown above, the
highest S/N values were obtained for the protonated forms of
nelfinavir, indinavir, and saquinavir, while lopinavir and ritonavir
were best detected as potassiated ions. Thus a tradeoff was needed
in the preparation of the DHB solution, i.e., preparation with or
without potassium iodide. Currently, Kaletra is the most widely
used HIV-1 protease inhibitor. Kaletra is a preparation of lopinavir
together with ritonavir which serves as a pharmacokinetic booster.
Because of the clinical importance of lopinavir and ritonavir, we
added potassium iodide to the matrix solution for the quantitative
analysis of HIV-1 protease inhibitors in lysates of peripheral blood
mononuclear cells. In addition, DMSO was added to the matrix
solution to enhance the quantitative precisions.
Stable isotope labeled internal standards would serve as the
best internal standards for quantitative MALDI experiments.
However, these were not commercially available for the tested
HIV-1 protease inhibitors. Therefore, we chose to use nelfinavir
as the internal standard for the quantitative analysis of indinavir,
lopinavir, saquinavir, and ritonavir. For the quantitative analysis
of nelfinavir, we used indinavir as the internal standard. Figure 1
shows the mass spectrum of lopinavir and nelfinavir (internal
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DHB + KI + DMSO
[analyte + K]+
nelfinavir 1000 5179 2151 552 745
indinavir 1000 1363 1820 212 627
lopinavir 1000 284 149 1680 2283
saquinavir 250 5476 5924 1125 1597
ritonavir 1000 479 632 845 2933
a A mixture of five pure HIV-1 protease inhibitors was analyzed using four different DHB preparations (see Experimental Section). The
concentration per spot on the target plate was 1 pmol for nelfinavir, indinavir, lopinavir, and ritonavir and 250 fmol for saquinavir. Four technical
replicates, i.e., four different spots on the target plate, were measured for each sample.
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standard) in a lysate of 1 × 106 PBMC (125 fmol lopinavir and 1
pmol nelfinavir per spot on the target plate). It can be seen from
this figure that the ionization efficiency of lopinavir is ap-
proximately a factor of 4 larger than that for nelfinavir. This factor
remains constant over the entire concentration range, and accurate
and precise quantitative analysis of the HIV protease inhibitors is
thus possible using a chemical analogue as the internal standard.
Table 3 shows the quantitative performance of the MALDI-
FTICR assay for the five HIV-1 protease inhibitors. The mean
quantitative precisions, expressed as % relative standard deviation,
were 6.4% for saquinavir, 7.3% for lopinavir, 8.5% for ritonavir, 11.1%
for indinavir, and 7.2% for nelfinavir. The mean analyte-to-internal
standard ratios of the analysis of three technical replicates were
used to calculate the drug concentrations in the samples. The
mean quantitative accuracies for the quality control (QC) samples,
expressed as % deviation from the theoretical concentration, were
4.5% for saquinavir, 6.0% for lopinavir, 5.9% for ritonavir, 6.6% for
indinavir, and 8.0% for nelfinavir. The measured drug concentra-
tions for the individual quality control samples were all within
85–117% of the theoretical concentrations. The above shows that
MALDI-FTICR can be used for accurate quantitative analysis of
HIV-1 protease inhibitors in cell lysates.
Table 2. The Effect of DMSO and Potassium Iodide on the Quantitative Precisions (% CV) of Five HIV Protease
Inhibitorsa
internal standard
nelfinavir indinavir lopinavir saquinavir ritonavir
DMSO - DMSO + DMSO - DMSO + DMSO - DMSO + DMSO - DMSO + DMSO - DMSO +
analyte NFV KI - 11.1 1.8 26.1 11.3 21.8 6.0 16.2 8.5
KI + 15.7 1.9 31.1 3.4 4.8 6.3 17.1 5.0
IDV KI - 10.8 1.8 35.8 12.8 28.7 5.5 14.5 9.0
KI + 16.3 1.9 47.0 3.3 18.9 5.4 8.0 4.5
LPV KI - 22.0 10.3 30.9 11.5 16.6 10.7 29.5 7.4
KI + 31.6 3.4 45.8 3.2 33.1 3.3 47.3 2.9
SQV KI - 20.0 5.7 23.5 5.4 15.0 11.7 17.6 5.3
KI + 4.9 6.4 17.4 5.3 29.2 3.4 17.5 3.3
RTV KI - 15.9 8.6 16.7 8.9 27.9 7.3 19.9 5.1
KI + 18.1 5.0 7.9 4.4 49.1 2.9 20.4 3.2
a A mixture of five pure HIV-1 protease inhibitors was analyzed using four different DHB preparations (see Experimental Section). One protease
inhibitor was chosen as the internal standard, and the remaining four protease inhibitors served as analytes. Subsequently, the analyte-to-internal
standard ratios were calculated. The signal-to-noise ratios (S/N) for the potassiated monoisotopic peaks were used when DHB was used with the
addition of potassium iodide. The S/N for the protonated monoisotopic peaks were used when DHB was used without the addition of potassium
iodide. This procedure was repeated until each protease inhibitor had served as the internal standard. Reported values in the tables are the %
relative standard deviations (RSD) for the analyte-to-internal standard ratios. The concentration per spot on the target plate was 1 pmol for nelfinavir,
indinavir, lopinavir, and ritonavir and 250 fmol for saquinavir. Four technical replicates were measured of each sample.
Figure 1. Analysis of lopinavir in a lysate of PBMC. Lopinavir and nelfinavir were spiked in a lysate of 1 × 106 PBMC. The monoisotopic peak
of potassiated lopinavir had a S/N of 66 (125 fmol per spot on the target plate). The monoisotopic peak of nelfinavir had a S/N 119 (1 pmol per
spot on the target plate). The inset shows a magnification of the lopinavir signal. The measured mass of the monoisotopic peak of potassiated
lopinavir was 667.325 75 Da. The theoretical mass is 667.325 63 Da corresponding to a mass deviation of +0.18 ppm. An external mass
calibration was used. The y-axis is in arbitrary units.
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Selectivity. FTICR mass spectrometry provides currently the
highest mass accuracy and resolution among mass analyzers.
Higher mass accuracy and resolution result in a better selectivity
of the assay. We typically obtain resolutions of 100 000 (fwhm).
The mean mass errors for the HIV-1 protease inhibitors in the
QC samples were-0.05 ppm for saquinavir, 0.11 ppm for lopinavir,
-0.21 ppm for ritonavir, 0.07 ppm for indinavir, and -0.28 ppm
for nelfinavir. Figure 2 shows the histogram of all mass errors
for the HIV protease inhibitors in the QC samples. The average
mass error for all measurements was -0.05 ppm, the standard
deviation was 0.34 ppm, and the root-mean-square was 0.34 ppm.
These mass errors were obtained using an external mass calibra-
tion. Internal calibration could result in even smaller mass errors.
CONCLUSIONS
We have shown that MALDI-FTICR can be used for precise
and accurate quantitative analysis of HIV-1 protease inhibitors in
PBMC lysates. This assay was developed for future studies on
the intracellular pharmacokinetics of HIV protease inhibitors in
PBMCs obtained from HIV-infected adults and children receiving
therapy. The lower limits of quantification needed for such studies
are thus a direct consequence of the amount of material that can
be obtained from these patients. One million PBMCs can be
obtained from a blood sample of 1–2 mL, which is a suitable
volume of blood to draw from HIV-1 infected adults and children.
The lower limits of quantification (LLOQ) for HIV-1 protease
inhibitors in PBMC lysates using the MALDI-FTICR assay were
4 fmol for saquinavir, 16 fmol for lopinavir, 31 fmol for ritonavir,
and 100 fmol for indinavir and nelfinavir. These are however the
“technical” LLOQs, i.e., the amount of drug in a single spot on
the target plate. We dissolved the dried lysates of 1 × 106 PBMCs
in 10 µL of solvent and subsequenlty deposited 1 µL of this solution
on different spots on the target plate. The minimum amount of
drug present in the dried lysates should thus be a factor of 10
higher in order for this assay to quantify the drugs. The
“biological” LLOQs are thus 40 fmol for saquinavir, 160 fmol for
lopinavir, 310 fmol for ritonavir, and 1 pmol for indinavir and
nelfinavir per million PBMCs. The reported minimum intracellular
concentrations (Cmin or Cpredose) of HIV-1 protease inhibitors in
HIV-1 infected adults are 6.4 pmol/(1 × 106 PBMC) for lopinavir,37
850 fmol/(1 × 106 PBMC) for ritonavir,37 450 fmol/(1 × 106
PBMC) for saquinavir,38 87 fmol/(1 × 106 PBMC) for indinavir,39
and 2.1 pmol/(1 × 106 PBMC) for nelfinavir.40 Except for indinavir,
the MALDI-FTICR assay can thus be used for quantitative analysis
of HIV-1 protease inhibitors in 1 000 000 PBMCs.
The LLOQs obtained by our MALDI-FTICR assay are compa-
rable to those obtained using the MS-mode of a MALDI-TOF mass
spectrometer.8,9 The resolving power and mass accuracy of the
MALDI-FTICR assay is superior compared to that of a MALDI-
TOF. Thus, using the MS-mode, the MALDI-FTICR assay is more
selective than the MALDI-TOF assay. In addition, we found that
MALDI-FTICR has a larger dynamic range than MALDI-TOF.8,41
Notari et al. used tandem mass spectrometry (MS/MS) on a
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saquinavir 4 4096 6.4 (5.1) 4.5 (3.0) -0.05 (0.26)
lopinavir 16 2000 7.3 (4.2) 6.0 (5.2) +0.11 (0.30)
ritonavir 31 2000 8.5 (3.8) 5.9 (3.6) -0.21 (0.46)
indinavir 100 6400 11.1 (4.7) 6.6 (4.2) +0.07 (0.14)
nelfinavir 100 6400 7.2 (5.1) 8.0 (4.0) -0.28 (0.19)
a LLOQ ) lower limit of quantification. ULOQ ) upper limit of quantification. fmol ) femtomole. % RSD ) relative standard deviation of the
mean analyte-to-IS ratio for each calibrator in %. % dev ) mean absolute deviation of the measured concentration from the real concentration in %.
ppm ) mean deviation of the measured mass from the real mass in parts-per-million. The precisions and accuracies are based on three measurements
of each calibrator of each sample set (total of two sample sets). The reported mass deviations are the mean mass accuracies for all measured
samples of sample sets 1 and 2 combined. The mean standard deviations are reported between parentheses.
Figure 2. Histogram of mass errors. The histogram shows the mass
errors in ppm for the five protease inhibitors (total of 208 measure-
ments) using an external mass calibration. A quadratic mass calibra-
tion equation was used. The line shows the Gaussian distribution of
the data.
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in human plasma and obtained a LLOQ of 2.5 fmol/µL for lopinavir
and ritonavir.19 To the best of our knowledge, three LC-MS/
MS methods for quantitative analysis of antiretroviral drugs in
PBMC have been described in detail.42–44 Jemal et al. obtained a
LLOQ of 5 fmol/(1 × 106 PBMC) for atazanavir.43 Rouzes et al.
obtained a LLOQ of 3 pmol/(3 × 106 PBMC) for lopinavir, 1 pmol/
(3 × 106 PBMC) for ritonavir, and 2 pmol/(3 × 106 PBMC) for
saquinavir.44 Colombo et al. obtained LLOQ of 5 fmol for ritonavir,
6 fmol for lopinavir, 6 fmol for saquinavir, 7 fmol for indinavir,
and 9 fmol for nelfinavir (minimum amount of quantifiable drug
on column).42 Our LLOQs obtained for the HIV protease inhibitors
in PBMC lysates using MALDI-FTICR are roughly comparable
to those obtained by LC-MS/MS. The sample analysis time of
the above-described LC-MS/MS methods range from 4 to 20
min. The measurement of one technical replicate takes 3 min
using the MALDI-FTICR assay. In this study, we have measured
three technical replicates of each sample, the analysis time for
one sample is thus 9 min. This is much slower compared to
MALDI-TOF and MALDI-QqQ measurements.1,8 Sophisticated
spotting devices, such as electrospray sample deposition and inkjet
printer technologies, may improve the quantitative precisions of
the measurements.
Sample volumes typically used in MALDI mass spectrometry
are on the order of 1 µL. The challenge for successful application
of MALDI mass spectrometry for quantitative analysis of drugs
is to concentrate analytes in such a small volume in a reproducible
manner. In previous studies, we dissolved the dried PBMC lysates
in 100 and 25 µL and subsequently spotted 1 µL.8,9 In the present
study, we dissolved the dried PBMC lysates in 10 µL of solvent.
We found that dissolving the dried lysates in less than 10 µL in a
reproducible way is difficult. Spotting larger volumes than 1 µL
may be used to overcome this problem.
Currently, LC-ESI-MS/MS is the standard for the quantitative
analysis of drugs. In this study we have developed a strategy for
the quantitative assessment of drugs in biological materials by
MALDI-FTICR. Our results demonstrate that MALDI-FTICR mass
spectrometry can be successfully used for the precise, accurate,
selective, and rapid quantitative analysis of drugs in biological
materials. In particular the lower limits obtained for the quantifica-
tion of HIV-1 protease inhibitors in cell lysates allow clinical
application of the MALDI-FTICR technique.
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